Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by NWI Management LP

Key Points

• NWI Management LP has significantly increased its shareholding in Teva Pharmaceutical Industries by 130.6%, owning 1,660,000 shares worth approximately $25.5 million.
• Teva reported earnings of $0.66 per share for the last quarter, surpassing estimates and showing a slight increase in revenue compared to the previous year.
• The company has set its FY 2025 guidance at 2.500-2.600 EPS, with current market analysts giving an average target price of $24.71 and a general "Buy" rating for the stock.

NWI Management LP lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 130.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,660,000 shares of the company's stock after acquiring an additional 940,000 shares during the period. Teva Pharmaceutical Industries accounts for about 3.2% of NWI Management LP's investment portfolio, making the stock its 11th largest position. NWI Management LP owned 0.15% of Teva Pharmaceutical Industries worth $25,514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of the business. Ion Asset Management Ltd. raised its holdings in Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock valued at $599,945,000 after buying an additional 2,383,500 shares during the period. Menora Mivtachim Holdings LTD. raised its holdings in Teva Pharmaceutical Industries by 2.8% in the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after buying an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after buying an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after buying an additional 22,044,407 shares during the period. Finally, Duquesne Family Office LLC raised its holdings in Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after buying an additional 5,882,350 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several research reports. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Up 2.5%

Shares of NYSE:TEVA traded up $0.46 during midday trading on Friday, reaching $18.94. The company had a trading volume of 7,802,703 shares, compared to its average volume of 9,638,927. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock's fifty day moving average price is $17.04 and its 200-day moving average price is $16.39. The stock has a market capitalization of $21.72 billion, a P/E ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.